Abstract
Thrombolytic agents play a major role in the treatment of cardiovascular diseases. Streptokinase is the prominently commercialized thrombolytic drug used for the treatment of cardiovascular diseases. The later studies on staphylokinase (SaK) showed promising results as an alternative fibrinolytic drug. The present study explores the isolation, production and purification of SaK producing Staphylococcus sp. from milk samples. The potent isolate MSA4 of Staphylococcus sp. was selected for production and purification of SaK. The total activity and specific activity of purified staphylokinase was found to be 1266 IU mL-1 and 815.5 IU mg-1, respectively. The partially purified enzyme was lysed the euglobulin clot completely within 18 h of incubation and the purified enzyme showed 79% of blood clot lysis activity.
Keywords: Clot buster, euglobulin clot, Staphylococcus sp., staphylokinase.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Evaluation on Clot Buster Activity of Staphylokinase from Staphylococcus sp.
Volume: 12 Issue: 2
Author(s): V. Mohanasrinivasan, C. Subathra Devi, Sukanya Saha, Lubbnaz Nagarchi, B. Vaishnavi and S. J. Naine
Affiliation:
Keywords: Clot buster, euglobulin clot, Staphylococcus sp., staphylokinase.
Abstract: Thrombolytic agents play a major role in the treatment of cardiovascular diseases. Streptokinase is the prominently commercialized thrombolytic drug used for the treatment of cardiovascular diseases. The later studies on staphylokinase (SaK) showed promising results as an alternative fibrinolytic drug. The present study explores the isolation, production and purification of SaK producing Staphylococcus sp. from milk samples. The potent isolate MSA4 of Staphylococcus sp. was selected for production and purification of SaK. The total activity and specific activity of purified staphylokinase was found to be 1266 IU mL-1 and 815.5 IU mg-1, respectively. The partially purified enzyme was lysed the euglobulin clot completely within 18 h of incubation and the purified enzyme showed 79% of blood clot lysis activity.
Export Options
About this article
Cite this article as:
Mohanasrinivasan V., Devi Subathra C., Saha Sukanya, Nagarchi Lubbnaz, Vaishnavi B. and Naine S. J., Evaluation on Clot Buster Activity of Staphylokinase from Staphylococcus sp., Cardiovascular & Hematological Agents in Medicinal Chemistry 2014; 12 (2) . https://dx.doi.org/10.2174/1871525712666141106102809
DOI https://dx.doi.org/10.2174/1871525712666141106102809 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
Current Pharmaceutical Design Spin Trapping: An Essential Tool for the Study of Diseases Caused by Oxidative Stress
Current Topics in Medicinal Chemistry Drug Development from Natural Resource: A Systematic Approach
Mini-Reviews in Medicinal Chemistry Anti-Inflammatory and Anti-Neoplastic Actions of Resveratrol
Current Nutrition & Food Science Porphyromonas gingivalis Gingipains: The Molecular Teeth of a Microbial Vampire
Current Protein & Peptide Science TRP Channels in Respiratory Pathophysiology: the Role of Oxidative, Chemical Irritant and Temperature Stimuli
Current Neuropharmacology Pyrimidine-fused Dinitrogenous Penta-heterocycles as a Privileged Scaffold for Anti-Cancer Drug Discovery
Current Topics in Medicinal Chemistry Nutraceuticals for Metabolic Syndrome Management: From Laboratory to Benchside
Current Vascular Pharmacology Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments
Current Drug Targets KIR Molecules: Recent Patents of Interest for the Diagnosis and Treatment of Several Autoimmune Diseases, Chronic Inflammation, and B-cell Malignancies
Recent Patents on DNA & Gene Sequences Do Adult Stem Cells Ameliorate the Damaged Myocardium? Human Cord Blood as a Potential Source of Stem Cells
Current Vascular Pharmacology Outcomes of Anticoagulant Therapy with Low-Molecular-Weight Heparin (LMWH) and Warfarin for Thromboangiitis Obliterans (TAO)
Current Vascular Pharmacology Nanomaterials of Natural Bioactive Compounds for Wound Healing: Novel Drug Delivery Approach
Current Drug Delivery Long-Term Bronchodilator Inhaled Therapy in COPD: The Role of Tiotropium Bromidum
Reviews on Recent Clinical Trials Host Microbiomes in Tumor Precision Medicine: How far are we?
Current Medicinal Chemistry Plasminogen Activator Inhibitor-1 in Vascular Thrombosis
Current Drug Targets Vitamin A in Prevention of Bronchopulmonary Dysplasia
Current Pharmaceutical Design Management of Vasculopathy in Connective Tissue Disease
Current Rheumatology Reviews Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug?
Current Neuropharmacology Clinical Significance of Pleiotropic Effects of Statins: Lipid Reduction and Beyond
Current Medicinal Chemistry